Exceptional Response to 177-Lutetium PSMA in Prostate Cancer Harboring DNA Repair Defects

[Balsam01]

This is only a case study but results are interesting.

Exceptional Response to 177-Lutetium PSMA in Prostate Cancer Harboring DNA Repair Defects

JCO clinical cancer informatics



 Get Topic Alerts

TAKE-HOME MESSAGE

•This case study reports an exceptional response to 177lutetium PSMA in a patient with metastatic castration-resistant prostate cancer with DNA repair defects, including frameshift mutation in exon 11 of the BRCA2 gene.

•As PSMA-targeted small molecules (such as 177lutetium) are being increasingly tested, with a number of clinical trials with very promising results, this case suggests that we may be able to identify patients who are more likely to respond to these therapies.

– Pedro Barata, MD, MSc

abstract

This abstract is available on the publisher's site.

Access this abstract now 

Prostate-specific membrane antigen (PSMA) is a cell surface protein that is often overexpressed on prostate cancer cells. PSMA-targeted small molecules bound to 177Lutetium (177Lu), a medium energy B-emitter, have been administered as a targeted therapy for metastatic prostate cancer; the PSMA-targeted small molecule binds to PSMA on the cancer cell surface and is internalized, leading to delivery of a potent but targeted dose of radiation to the cell. A small molecule commonly used for this purpose is PSMA-617, a human PSMA-targeting ligand that can be conjugated to 177Lu. 177LuPSMA-617 therapy has shown great promise in early-phase trials, with a prostate-specific antigen (PSA) response rate of 57% in a phase II prospective study, and randomized trials are currently recruiting internationally. De novo and acquired resistance are common, however, and biomarkers are needed to guide patient selection and rationalize combinatorial approaches.

[NPfisherman]

A PSA response rate of 57%.... NICE !!! Thanks for posting....

Fish